Erythropoietic Protoporphyria
18
0
0
15
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
0.0%
0 terminated out of 18 trials
100.0%
+13.5% vs benchmark
28%
5 trials in Phase 3/4
60%
9 of 15 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 15 completed trials
Clinical Trials (18)
Pharmacokinetics of Afamelanotide in Erythropoietic Protoporphyria Patients
Effect of Oral Cimetidine in the Protoporphyrias
Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants With EPP
HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP
Protection Against Visible Light by Dihydroxyacetone in Erythropoietic Protoporphyria
Iron Therapy in Erythropoietic Protoporphyria
Phase III Confirmatory Study in Erythropoietic Protoporphyria (EPP)
A Safety Extension Study in Patients With Erythropoietic Protoporphyria (EPP)
Oral Iron for Erythropoietic Protoporphyrias
Erythropoietic Protoporphyrias: Studies of the Natural History, Genotype-Phenotype Correlations, and Psychosocial Impact
Phase II Confirmatory Study in Erythropoietic Protoporphyria (EPP)
Multicentre Phase III Erythropoietic Protoporphyria Study
Phase III Confirmatory Study in Erythropoietic Protoporphyria
Light Exposure Patterns and Symptoms Among Patients With Erythropoietic Protoporphyria
Sorbent Therapy of the Cutaneous Porphyrias
Study of Cysteine Hydrochloride for Erythropoietic Protoporphyria
Phase III Study of L-Cysteine in Patients With Erythropoietic Protoporphyria
Does Exercise and Heat Increase the Lightsensibility in Patients With Erythropoietic Protoporphyria